Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3476
Fax+1 617-582-7875
Are you Dr. Aguirre?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Andrew Aguirre, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is an Instructor in Medicine at Massachusetts General Hospital.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2010
Harvard Medical SchoolClass of 2007
Certifications & Licensure
MA State Medical License 2010 - 2026
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma.Bach Ardalan, Aaron Ciner, Yasmine Baca, Andrew Hinton, Sourat Darabi
Clinical Cancer Research. 2025-03-17 - Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma.Josephine Yates, Camille Mathey-Andrews, Jihye Park, Amanda Garza, Andréanne Gagné
Biorxiv. 2025-03-03 - Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards
Nature. 2024-11-01
Authored Content
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Diabetes, Weight Change, and Pancreatic Cancer RiskAugust 2020
- Join now to see all
Press Mentions
KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?September 9th, 2024- Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?August 20th, 2024
- Driving Progress Against RAS-Driven CancersMarch 29th, 2023
- Join now to see all
Grant Support
- Mechanisms of response and resistance to KRAS inhibition in pancreatic cancerDANA-FARBER CANCER INST2023–2027
- Mechanisms of response and resistance to KRAS inhibition in pancreatic cancerDANA-FARBER CANCER INST2023–2027
- Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivityDANA-FARBER CANCER INST2022–2027
